Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.

Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafà R, Magri E, Lunardi M, Munerato G, Querzoli G, Maestri I, Ulazzi L, Nenci I, Croce CM, Lanza G, Querzoli P, Negrini M.

J Pathol. 2011 Sep;225(1):43-53. doi: 10.1002/path.2915. Epub 2011 Jun 1.

2.

p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features.

Biganzoli E, Coradini D, Ambrogi F, Garibaldi JM, Lisboa P, Soria D, Green AR, Pedriali M, Piantelli M, Querzoli P, Demicheli R, Boracchi P, Nenci I, Ellis IO, Alberti S.

Jpn J Clin Oncol. 2011 Feb;41(2):172-9. doi: 10.1093/jjco/hyq227. Epub 2011 Jan 2.

PMID:
21199790
3.

An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer.

Querzoli P, Coradini D, Pedriali M, Boracchi P, Ambrogi F, Raimondi E, La Sorda R, Lattanzio R, Rinaldi R, Lunardi M, Frasson C, Modesti F, Ferretti S, Piantelli M, Iacobelli S, Biganzoli E, Nenci I, Alberti S.

Br J Cancer. 2010 Dec 7;103(12):1835-9. doi: 10.1038/sj.bjc.6605991. Epub 2010 Nov 9.

4.

High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies.

Tinari N, Lattanzio R, Querzoli P, Natoli C, Grassadonia A, Alberti S, Hubalek M, Reimer D, Nenci I, Bruzzi P, Piantelli M, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO).

Int J Cancer. 2009 Jan 15;124(2):333-8. doi: 10.1002/ijc.23970.

5.
6.

Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients.

Querzoli P, Pedriali M, Rinaldi R, Lombardi AR, Biganzoli E, Boracchi P, Ferretti S, Frasson C, Zanella C, Ghisellini S, Ambrogi F, Antolini L, Piantelli M, Iacobelli S, Marubini E, Alberti S, Nenci I.

Clin Cancer Res. 2006 Nov 15;12(22):6696-701.

7.

Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods.

Ambrogi F, Biganzoli E, Querzoli P, Ferretti S, Boracchi P, Alberti S, Marubini E, Nenci I.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):781-90.

8.

MicroRNA gene expression deregulation in human breast cancer.

Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM.

Cancer Res. 2005 Aug 15;65(16):7065-70.

9.

Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT).

Paradiso A, Volpe S, Iacobacci A, Marubini E, Verderio P, Costa A, Daidone MG, Marchetti A, Mottolese M, Amadori D, De Paola F, Saragoni L, Medri L, Nenci I, Querzoli P, Gion M, Dittadi R, Plebani M, Orlando C, Bevilacqua G, Silvestrini R; Italian Network for Quality Assessment of Tumor Biomarkers.

Int J Biol Markers. 2002 Jul-Sep;17(3):201-14.

PMID:
12408472
10.

Mesectodermal leiomyoma exclusively involving the posterior choroid.

Perri P, Paduano B, Incorvaia C, Costagliola C, Parmeggiani F, Rossi S, Lamberti G, Nenci I, Sebastiani A.

Am J Ophthalmol. 2002 Sep;134(3):451-4.

PMID:
12208265
11.

Loss of methylation at chromosome 11p15.5 is common in human adult tumors.

Scelfo RA, Schwienbacher C, Veronese A, Gramantieri L, Bolondi L, Querzoli P, Nenci I, Calin GA, Angioni A, Barbanti-Brodano G, Negrini M.

Oncogene. 2002 Apr 11;21(16):2564-72.

12.

Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.

Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, Pedriali M, Matteuzzi M, Maestri I, Nenci I.

Breast Cancer Res Treat. 2001 Mar;66(2):135-42.

PMID:
11437099
13.

[Aneurysmatic fibrous histiocytoma: case report and reivew of the literature].

Albonico G, Pellegrino G, Maisano M, Africa G, Pedriali M, Nenci I.

Pathologica. 2001 Apr;93(2):136-8. Review. Italian.

PMID:
11428292
14.

Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes.

Calin GA, Gafà R, Tibiletti MG, Herlea V, Becheanu G, Cavazzini L, Barbanti-Brodano G, Nenci I, Negrini M, Lanza G.

Int J Cancer. 2000 May 20;89(3):230-5.

15.

Quantitative immunoprofiles of breast cancer performed by image analysis.

Querzoli P, Albonico G, Ferretti S, Rinaldi R, Magri E, Nenci I.

Anal Quant Cytol Histol. 1999 Apr;21(2):151-60.

PMID:
10560485
16.

Biological profile of in situ breast cancer investigated by immunohistochemical technique.

Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I.

Cancer Detect Prev. 1998;22(4):313-8.

PMID:
9674874
17.

Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression.

Querzoli P, Albonico G, Ferretti S, Rinaldi R, Beccati D, Corcione S, Indelli M, Nenci I.

Cancer. 1998 Jul 1;83(1):89-97.

PMID:
9655297
18.

90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells.

Fusco O, Querzoli P, Nenci I, Natoli C, Brakebush C, Ullrich A, Iacobelli S.

Int J Cancer. 1998 Feb 20;79(1):23-6.

19.

Combined and sequential expression of p53, Rb, Ras and Bcl-2 in bronchial preneoplastic lesions.

Ferron PE, Bagni I, Guidoboni M, Beccati MD, Nenci I.

Tumori. 1997 Mar-Apr;83(2):587-93.

PMID:
9226026
20.

MIB-1 proliferative activity in invasive breast cancer measured by image analysis.

Querzoli P, Albonico G, Ferretti S, Rinaldi R, Magri E, Indelli M, Nenci I.

J Clin Pathol. 1996 Nov;49(11):926-30.

21.

Biological heterogeneity of breast carcinoma in situ.

Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I.

Ann N Y Acad Sci. 1996 Apr 30;784:458-61. No abstract available.

PMID:
8651598
22.

Biological staging of incipient, in situ, and invasive breast carcinomas.

Querzoli P, Albonico G, Ferretti S, Rinaldi R, Nenci I.

Ann N Y Acad Sci. 1996 Apr 30;784:381-94. No abstract available.

PMID:
8651586
23.

Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters.

Albonico G, Querzoli P, Ferretti S, Magri E, Nenci I.

Pathol Res Pract. 1996 Feb;192(2):117-23.

PMID:
8692711
24.

Application of quantitative analysis to biologic profile evaluation in breast cancer.

Querzoli P, Ferretti S, Albonico G, Magri E, Scapoli D, Indelli M, Nenci I.

Cancer. 1995 Dec 15;76(12):2510-7.

PMID:
8625078
25.

Cancer incidence and mortality in the province of Ferrara 1989-1990.

Ferretti S, Tassinari D, Albonico G, Nenci I.

Tumori. 1995 Sep-Oct;81(5):321-9.

PMID:
8804447
26.

Clinical usefulness of estrogen receptor immunocytochemistry in human breast cancer.

Querzoli P, Ferretti S, Marzola A, Tassinari D, Indelli M, Marchetti E, Fabris G, Nenci I.

Tumori. 1992 Oct 31;78(5):287-90.

PMID:
1494801
27.

Suppression of tumorigenesis by the breast cancer cell line MCF-7 following transfer of a normal human chromosome 11.

Negrini M, Castagnoli A, Sabbioni S, Recanatini E, Giovannini G, Possati L, Stanbridge EJ, Nenci I, Barbanti-Brodano G.

Oncogene. 1992 Oct;7(10):2013-8.

PMID:
1408142
28.
29.

Linkage of biopsy, cancer, and population records aimed at the estimation of family risks in neoplasia: a pilot study.

Barrai I, Nenci I, Guidi E, Dell'Acqua G, Formica G, Barbujani G, Marzola A, Marani G, Barale R, Beretta M.

J Epidemiol Community Health. 1991 Jun;45(2):107-11.

30.

Immunohistochemical expression of c-erbB-2 in human breast cancer by monoclonal antibody: correlation with lymph node and ER status.

Querzoli P, Marchetti E, Fabris G, Marzola A, Ferretti S, Iacobelli S, Hazan R, King CR, Nenci I.

Tumori. 1990 Oct 31;76(5):461-4.

PMID:
1979454
31.
32.

Fine needle aspiration cytology of thyroid gland diseases.

Altavilla G, Pascale M, Nenci I.

Acta Cytol. 1990 Mar-Apr;34(2):251-6.

PMID:
2321461
33.

Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody.

Marchetti E, Querzoli P, Marzola A, Bagni A, Ferretti S, Fabris G, Nenci I.

Mod Pathol. 1990 Jan;3(1):31-5.

PMID:
2308919
34.

RAP-5 binding in formalin-fixed samples.

Altavilla G, Rossi S, Nenci I, Corallini A.

Hum Pathol. 1989 Jun;20(6):608-9. No abstract available.

PMID:
2656501
35.

Monoclonal antibodies for specific immunoperoxidase detection of Campylobacter pylori.

Negrini R, Lisato L, Cavazzini L, Maini P, Gullini S, Basso O, Lanza G Jr, Garofalo M, Nenci I.

Gastroenterology. 1989 Feb;96(2 Pt 1):414-20.

PMID:
2642876
36.

Immunocytochemical detection of estrogen receptors by staining with monoclonal antibodies on cytologic specimens of human breast cancer.

Marchetti E, Bagni A, Querzoli P, Durante E, Marzola A, Fabris G, Nenci I.

Acta Cytol. 1988 Nov-Dec;32(6):829-34.

PMID:
2462317
37.

Expression of p21 ras gene products in breast cancer relates to histological types and to receptor and nodal status.

Querzoli P, Marchetti E, Bagni A, Marzola A, Fabris G, Nenci I.

Breast Cancer Res Treat. 1988 Sep;12(1):23-30.

PMID:
3058236
38.

Commentary on human mammary preneoplasia. The estrogen receptor-promotion hypothesis.

Nenci I, Marchetti E, Querzoli P.

J Steroid Biochem. 1988;30(1-6):105-6.

PMID:
3386240
39.

Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: correlation with estrogen receptor assay by dextran-coated charcoal method.

Marchetti E, Querzoli P, Moncharmont B, Parikh I, Bagni A, Marzola A, Fabris G, Nenci I.

Cancer Res. 1987 May 1;47(9):2508-13.

40.

Pathophysiology of estrogen receptors in mammary tissue by monoclonal antibodies.

Fabris G, Marchetti E, Marzola A, Bagni A, Querzoli P, Nenci I.

J Steroid Biochem. 1987;27(1-3):171-6.

PMID:
3695478
41.

Expression and modulation of estrogen receptors in human breast cancer.

Nenci I.

J Steroid Biochem. 1985 Dec;23(6B):1093-6.

PMID:
4094428
42.

Charting steroid-cell interactions in normal and neoplastic tissues. Update 1983.

Nenci I.

Prog Clin Biol Res. 1984;142:23-36. No abstract available.

PMID:
6709657
43.

Prolactin and prolactin binding sites in human breast cancer cells.

Marchetti E, Rimondi AP, Querzoli P, Fabris G, Nenci I.

Prog Clin Biol Res. 1984;142:109-17. No abstract available.

PMID:
6324233
44.

Immunocytochemical demonstration of steroid receptors.

Marchetti E, Nenci I.

Recent Results Cancer Res. 1984;91:61-7. No abstract available.

PMID:
6203150
45.

Specific cell adhesion to estradiol-derivatized agarose beads.

Nenci I.

J Steroid Biochem. 1983 Jul;19(1A):109-11.

PMID:
6350715
46.

[Immunomorphology in oncology].

Rimondi AP, Cavazzini L, Nenci I.

Minerva Med. 1982 Apr 28;73(18):1139-44. Italian. No abstract available.

PMID:
6979009
47.
48.

The plasma membrane as an additional level of steroid-cell interaction.

Nenci I, Fabris G, Marzola A, Marchetti E.

J Steroid Biochem. 1981 Dec;15:231-4. No abstract available.

PMID:
7339249
49.

Affinity cytochemistry visualizes specific estrogen binding sites on the plasma membrane of breast cancer cells.

Nenci I, Marchetti E, Marzola A, Fabris G.

J Steroid Biochem. 1981 Nov;14(11):1139-46. No abstract available.

PMID:
7311527
50.

Estrogen receptor cytochemistry by fluorescent estrogen.

Nenci I, Dandliker WB, Meyers CY, Marchetti E, Marzola A, Fabris G.

J Histochem Cytochem. 1980 Oct;28(10):1081-8.

PMID:
7419900

Supplemental Content

Support Center